IL324833A - Crystal of a nitrogen-containing heterocyclic compound with an Nrf2 activating effect - Google Patents

Crystal of a nitrogen-containing heterocyclic compound with an Nrf2 activating effect

Info

Publication number
IL324833A
IL324833A IL324833A IL32483325A IL324833A IL 324833 A IL324833 A IL 324833A IL 324833 A IL324833 A IL 324833A IL 32483325 A IL32483325 A IL 32483325A IL 324833 A IL324833 A IL 324833A
Authority
IL
Israel
Prior art keywords
crystal
powder
compound
diffraction angles
diffraction
Prior art date
Application number
IL324833A
Other languages
English (en)
Hebrew (he)
Inventor
Iwata Tomoya
Takata Noriyuki
Kono Masato
Original Assignee
Chugai Pharmaceutical Co Ltd
Iwata Tomoya
Takata Noriyuki
Kono Masato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Iwata Tomoya, Takata Noriyuki, Kono Masato filed Critical Chugai Pharmaceutical Co Ltd
Publication of IL324833A publication Critical patent/IL324833A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IL324833A 2023-06-19 2024-06-18 Crystal of a nitrogen-containing heterocyclic compound with an Nrf2 activating effect IL324833A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023100075 2023-06-19
PCT/JP2024/022040 WO2024262491A1 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Publications (1)

Publication Number Publication Date
IL324833A true IL324833A (en) 2026-01-01

Family

ID=93935419

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324833A IL324833A (en) 2023-06-19 2024-06-18 Crystal of a nitrogen-containing heterocyclic compound with an Nrf2 activating effect

Country Status (9)

Country Link
EP (1) EP4696692A1 (cg-RX-API-DMAC7.html)
JP (1) JP7904995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20260023529A (cg-RX-API-DMAC7.html)
CN (1) CN121152792A (cg-RX-API-DMAC7.html)
AU (1) AU2024314540A1 (cg-RX-API-DMAC7.html)
IL (1) IL324833A (cg-RX-API-DMAC7.html)
MX (1) MX2025014082A (cg-RX-API-DMAC7.html)
TW (1) TW202504613A (cg-RX-API-DMAC7.html)
WO (1) WO2024262491A1 (cg-RX-API-DMAC7.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
US20190380992A1 (en) 2014-12-04 2019-12-19 Biogen Ma Inc. Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
GB202005852D0 (en) 2020-04-22 2020-06-03 C4X Discovery Ltd Therapeutic compounds
CN114507181B (zh) 2020-11-17 2024-03-26 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
CR20240325A (es) 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2

Also Published As

Publication number Publication date
TW202504613A (zh) 2025-02-01
JP7904995B2 (ja) 2026-08-13
MX2025014082A (es) 2026-01-07
AU2024314540A1 (en) 2025-11-27
KR20260023529A (ko) 2026-02-20
EP4696692A1 (en) 2026-02-18
JPWO2024262491A1 (cg-RX-API-DMAC7.html) 2024-12-26
CN121152792A (zh) 2025-12-16
WO2024262491A1 (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
CN103694236B (zh) 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物
CN109776445B (zh) 苯并噁二唑类化合物及其制备方法和医药用途
CN110582491B (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2023011513A1 (zh) Shp2抑制剂、包含其的药物组合物及其用途
CN114907387A (zh) 嘧啶并吡咯类kras抑制剂及其制备方法与应用
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
WO2021078301A1 (zh) 蛋白降解剂及其在疾病治疗中的应用
EP3789383B9 (en) Inhibitors of the trpc3 or trpc6 channel
CN105732614B (zh) 磺酰胺基芳基炔类化合物及其用途
CA2764653A1 (en) Tetracyclic compounds
JP7286299B2 (ja) 1-メチル-d-トリプトファンの塩及びプロドラッグ
CN110198938A (zh) 作为蛋白质聚集调节剂的双-杂芳基衍生物
CN110167937A (zh) 作为蛋白质聚集调节剂的二环双-杂芳基衍生物
JP2020002135A (ja) Creb結合タンパク質(cbp)の阻害
CN105102450A (zh) 作为PERK抑制剂的新颖的N-(2,3-二氢-1H-吡咯并[2,3-b]吡啶-5-基)-4-喹唑啉胺和N-(2,3-二氢-1H-吲哚-5-基)-4-喹唑啉胺衍生物
CN103923085B (zh) 具有刺猬通路拮抗剂活性的吡啶杂环化合物及其用途
AU2018340505A1 (en) Novel heterocyclic compounds as modulators of mGluR7
WO2017101796A1 (zh) 酞嗪酮衍生物、其制备方法及用途
WO2019189555A1 (ja) 複素環化合物
JP2021512942A (ja) トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびmGlu5受容体のモジュレータとしてのそれらの使用
AU2024314540A1 (en) Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
CA3291766A1 (en) Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
CN118496203A (zh) 喹喔啉类化合物及其医药用途
CN116640122A (zh) Ikzf2降解剂及包含其的药物组合物和用途
CN116535423B (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用